Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Asset disposition
Cert. of designation
Director departure
Appointed director
|
|
ALIMERA SCIENCES INC (ALIM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/18/2023 |
8-K
| Entered into consulting agreement, Appointed a new director|
Docs:
|
"Exhibit 2.1 PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc. May 17, 2023",
"RESOLVED, that a new Section 7 is hereby added to the Certificate of Designation as follows: consummate a Liquidation Transaction. SECOND: The foregoing amendments were duly adopted in accordance with the provisions of Section 103 and 242 of the DGCL. IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer on May 16, 2023. ALIMERA SCIENCES, INC.",
"In Witness Whereof, the Parties intending to be bound have caused this Commercial Supply Agreement to be executed by their duly authorized representatives as of the Effective Date. EYEPOINT PHARMACEUTICALS, INC. By: /s/ Nancy Lurker Name: Nancy Lurker Title: Chief Executive Officer ALIMERA SCIENCES, INC. By: /s/ Richard S. Eiswirth, Jr. Name: Richard S. Eiswirth, Jr. Title: Chief Executive Officer [Signature Page to Commercial Supply Agreement] EXHIBIT A PRODUCT SPECIFICATIONS [***] EXHIBIT B INITIAL ROLLING FORECAST [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]",
"Exhibit 10.2",
"Alimera Acquires U.S. Commercial Rights to YUTIQ®" |
|
| 03/27/2023 |
8-K
| Appointed a new director|
Docs:
|
"of the General Corporation Law of the State of Delaware)",
"CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law",
"CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law",
"COMMON STOCK PURCHASE WARRANT ALIMERA SCIENCES, INC.",
"SCHEDULE B Tranche 2 Closing Purchaser Entities Shares of Series B Convertible Preferred Stock Aggregate Purchase Price Velan Capital Master Fund LP 7,500 $7,500,000 Caligan Partners LP, as investment manager for Boothbay Absolute Return Strategies LP 2,625 $2,625,000 Caligan Partners LP, as investment manager for Boothbay Diversified Alpha Fund Master Fund LP 1,750 $1,750,000 Caligan Partners LP, as investment manager for Caligan Partners Master Fund LP 3,125 $3,125,000 Total 15,000 $15,000",
"ARTICLE IV REGISTRATION EXPENSES 4.1 Registration Expenses. All reasonable fees and expenses incident to the performance of or compliance with this Agreement , except as and to the extent specified in this Section 4.1, shall be borne by the Company whether or not a Registration Statement is filed by the Company or becomes effective and whether or not any Registrable Securities are sold pursuant to a Registration Statement. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Purchaser or, except to the extent provided for above or in the Transaction Documents, any legal fees or other costs of the Purchasers. The Company shall reimburse the Holders for the reasonable fees and disbursements of one legal counsel, which shall be Olshan...",
"Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility" |
|
| 10/02/2012 |
8-K
| Asset disposition, Certificate of designation filed, Appointed a new director|
Docs:
|
"EX-3.4(C)",
"Certificate of Designation of Series A Convertible Preferred Stock",
"EX-4.10(A)",
"EX-4.10(B)",
"EX-4.10(C)",
"EX-4.10(D)",
"EX-4.10(E)",
"Registration Rights Agreement",
"Amendment No. 1 to Securities Purchase Agreement",
"ALIMERA SCIENCES CLOSES $40 MILLION FINANCING Stockholders Approve the Issuance of Series A Preferred Stock and Warrants ATLANTA, GA. October 2, 2012 — Alimera Sciences, Inc. , a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Preferred Stock and warrants to purchase Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement. On October 1, 2012, the Company held a special stockholders meeting at which the stockholders approved the issuance of Series A Preferred and Warrants pursuant to applicable NASDAQ Listing Rules. “We believe the closing of this fin..." |
|
|
|